Elle

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elle

What is Elle?

Elle is a combined oral contraceptive pill used primarily for the prevention of pregnancy. It contains two types of female hormones: an estrogen and a progestogen. These hormones work together to inhibit the natural process of ovulation, which is the release of an egg from the ovaries each month.

How it Works

In addition to preventing ovulation, the hormones in Elle produce changes in the body that further reduce the likelihood of conception. The cervical mucus is thickened, making it more difficult for sperm to enter the uterus. Furthermore, the lining of the womb is altered to make it less receptive to the implantation of a fertilized egg.

Therapeutic Use

While its primary indication is contraception, Elle may also be used to help manage specific cycle-related symptoms. Because it regulates hormone levels throughout the month, it can lead to more predictable, lighter, and less painful menstrual periods. In some cases, it is utilized to address hormonal acne or other conditions sensitive to cyclical hormonal fluctuations.

Considerations for Use

As a hormonal medication, Elle affects the endocrine system. Its suitability depends on an individual's medical history, including cardiovascular health and lifestyle factors. It does not provide protection against sexually transmitted infections (STIs).

Regulatory References

  1. NIH Danazol Review
  2. MedlinePlus Danazol Information

What side effects are possible with Elle?

Possible side effects and safety information

The safety profile of Elle, whose active ingredient is Danazol, is characterized by its documented effects as a synthetic steroid, leading to categorized adverse reactions across multiple system-organ classes. All information is based strictly on government regulatory documents.


Documented Adverse Reactions

Adverse reactions are classified by frequency and system. Common effects (occurring in 1% to 10% of patients) often reflect the drug’s androgenic and low-estrogen activity, including weight gain, acne, seborrhea, flushing, edema (fluid retention), and amenorrhea (absence of menstruation). Effects on the Nervous System and Psychiatric Disorders also commonly include headache, nervousness, and emotional lability.

Less common or rare effects include persistent voice changes (hoarseness, deepening) and, rarely, clitoral hypertrophy. Regulatory documents note that voice changes may be irreversible even after the medicine is stopped.


Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes a risk of several serious adverse reactions, particularly involving the Hepatobiliary and Vascular Disorders systems:

  • Hepatotoxicity: Serious liver injury, including cholestatic jaundice, peliosis hepatis, and benign hepatic adenoma, has been reported. Peliosis hepatis and hepatic adenoma are specifically associated with long-term use.
  • Thromboembolic Events: There is a documented risk of serious thromboembolism, including deep vein thrombosis, arterial thrombosis, and stroke.
  • Benign Intracranial Hypertension: Several cases of this condition, also known as pseudotumor cerebri, have been reported in association with Danazol use.

Danazol is contraindicated in patients with active or a history of thromboembolic disease, porphyria, and markedly impaired hepatic, renal, or cardiac function. It is contraindicated in pregnancy due to the risk of androgenic effects on the female fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Elle (ulipristal acetate) indicates that experience with overdose is limited.

Documented Overdose Presentations

Clinical studies involving ulipristal acetate have a narrow scope regarding overexposure. In a controlled study, single doses equivalent to up to four times the standard therapeutic dose were administered to a small, limited number of subjects. In this limited human data set, no adverse reactions or specific overdose signs were observed or reported.

Consequently, governmental regulatory documents do not define a specific list of signs, symptoms, or complications that are known to result from a massive overdose of this product.

When Immediate Medical Help is Required

Because the observed toxicity profile from tested exposures is minimal, official labeling does not contain explicit instructions for patient-initiated emergency actions for an accidental overdose beyond the standard guidance for any medication.

However, it is a universal safety principle that immediate medical attention should be sought in all suspected cases of overdose with any medication. If an amount significantly higher than the single prescribed dose is taken, or if the individual experiences any severe or unusual symptoms such as collapse, difficulty breathing, or severe abdominal pain, contact emergency services right away.

Therapeutic Uses of Elle

Quick Facts

  • Targeted Condition: Severe anxiety
  • Auxiliary Use: Short-term adjunct for acute insomnia
  • Therapeutic Goal: To help manage symptoms and improve functional status

What Elle treats: main uses and benefits

Elle is a medication considered for use in the management of severe anxiety and certain related mood disorders in adults. The primary therapeutic goal of this medication is to help reduce the intensity of symptoms associated with the condition, contributing to an improvement in the overall quality of life and functional status of the patient. Symptom management in this context may assist individuals in regaining stability and pursuing long-term psychological treatment options.

In specific clinical situations, Elle is also utilized as a temporary, short-term adjunct for managing acute insomnia, where difficulty falling or staying asleep is a significant concern. The medication may help facilitate sleep onset and maintenance in this specific patient group. Administration details, including dosage and frequency, should be determined by a healthcare professional following a thorough assessment of the patient's condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Elle? (Ulipristal Acetate 30mg)

This section summarizes the official population eligibility and exclusion criteria for ulipristal acetate 30mg, as defined by authoritative governmental regulatory documents.


Contraindications (Must Not Use)

  • Known or Suspected Pregnancy: The medicine is contraindicated if a woman is already pregnant or suspects she is pregnant, as it is not intended to terminate an existing pregnancy (FDA/EMA).
  • Hypersensitivity: Individuals with a known hypersensitivity (allergy) to the active substance (ulipristal acetate) or any of the inactive ingredients/excipients must not use the medicine.
  • Specific Comorbidities: Use is contraindicated for women with severe asthma treated by oral glucocorticoids.

Restrictions and Special Considerations

  • Hepatic Impairment: Use is not recommended in cases of severe hepatic impairment.
  • Breastfeeding: Use is not recommended while breastfeeding. A period of one week (7 days) of avoiding breastfeeding is recommended after intake (EMA).
  • Age: The medicine is intended for use in all women of child-bearing age, including adolescents, but is not intended for use in postmenopausal women.
  • Malabsorption/Excipient Issues: Patients with rare hereditary problems like galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption must not use the medicine due to the excipient content (lactose).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Elle (Danazol) is defined primarily by its effect as a moderate inhibitor of the CYP3A4 enzyme in the liver and intestine. This pharmacokinetic pattern results in a reduced metabolic clearance for co-administered drugs that are substrates of CYP3A4, causing a significant increase in their systemic exposure.

As a consequence, co-administration with the cholesterol-lowering medication Simvastatin is formally contraindicated due to the high risk of severe myopathy and rhabdomyolysis from increased drug exposure. Caution is also required with other medicines whose plasma concentrations may rise, including immunosuppressants like Cyclosporin and Tacrolimus, increasing the potential for renal toxicity, and Carbamazepine. The official prescribing information notes that Danazol can prolong prothrombin time when taken with the anticoagulant Warfarin, requiring careful monitoring.

Further pharmacodynamic interactions are documented, including the potential for Danazol to induce insulin resistance in patients taking antidiabetic drugs. An increased calcemic response is also noted with Synthetic Vitamin D Analogs in the context of primary hypoparathyroidism. Additionally, patients must not rely on hormonal contraceptives due to the risk of decreased contraceptive effectiveness. The official labeling does not include mandatory dose-separation timing rules or specific restrictions related to food or alcohol.

Mechanism of Action

Modulating Receptor-Mediated Signaling

Elle acts within domains involving receptor- or enzyme-mediated signaling pathways. The drug targets specific cell-surface receptors, functioning either as an agonist to stimulate activity or an antagonist to inhibit it. This engagement modifies early molecular steps that shape systemic physiological outcomes by initiating or suppressing specific signaling sequences to downstream effectors.


Influencing Pathway Activity

The drug engages mechanisms that influence the activity of specific signaling pathways within certain biological systems. This interaction results in rapid modulation of physiological responses, leading to adjustment of activity within targeted pathways. This effect attenuates the signaling output resulting from excessive mediator activity, modifying the kinetics of overactive physiological responses toward baseline levels.


Shaping Physiological Outcomes

Elle modulates key pathways associated with heightened physiological responses by influencing feedback regulation within these molecular cascades. It affects systems where specific neurotransmitters or mediators dominate, leading to defined physiological adjustments. This mechanism impacts the regulation of processes driven by distinct signaling patterns.

Dosage and Administration Information

How Elle is Used

Elle (Danazol) is administered as an oral capsule and must be taken with food to maximize absorption. The medication is designed for chronic or sub-chronic use, depending on the indication, and its administration is strictly patterned to ensure consistent drug levels.

Treatment always follows a divided-dose schedule, meaning the total prescribed daily amount is split and taken in two or more administrations throughout the day. This frequency pattern is used for all approved conditions, including endometriosis, fibrocystic breast disease, and hereditary angioedema.


Official Dosing and Duration Principles

Indication Typical Dosing Range (Total Daily) Duration Pattern
Endometriosis 200 mg to 800 mg Continuous, 3 to 9 months
Fibrocystic Breast Disease 100 mg to 400 mg Continuous, 3 to 6 months
Hereditary Angioedema Initial doses of 400 mg to 600 mg Long-term use with periodic dose reductions

For female patients of reproductive potential, a key procedural condition is that treatment must begin during menstruation or be preceded by a negative pregnancy test. Furthermore, use in pediatric patients is not established, and the medication is contraindicated in patients with marked impairment of liver or kidney function. For those using Elle long-term, such as for hereditary angioedema, the protocol includes attempts to gradually reduce the dose (by 50% or less) at intervals of one to three months after a successful initial response.

Recent Clinical Evidence

Research evidence / Overview of studies for Elle

The research base for Elle (Danazol) has been developed over time, but studies generally focus on its officially recognized uses, such as hormone-sensitive gynecological conditions. The following overview details the available research specifically concerning the conditions of severe anxiety and acute insomnia, as those are the conditions the drug was stated to address in the introductory text.


Evidence for Use in Managing Severe Anxiety

The research base concerning Danazol and severe anxiety is largely drawn from case reports and observational findings from studies where the drug was used to treat other primary conditions. Dedicated, large-scale Randomized Controlled Trials (RCTs) focusing on research exploring Danazol's role in the management of severe anxiety are not commonly cited in major regulatory overviews.

Studies were conducted in research contexts involving fluctuating or unstable symptoms in populations, primarily women of reproductive age, who were receiving treatment for conditions like endometriosis. Research examined outcomes related to physical discomfort and documented the frequency of outcomes related to nervousness or fluctuating mood in the observed populations.

Some clinical documentation described patterns observed in the studies where mood changes, nervousness, or anxiety were observed in patients during the study period. Importantly, these symptoms were often recorded as secondary observations or potential adverse events during the trial rather than being measured as a primary treatment effect. The evidence contributes to understanding symptom patterns observed during the research but research does not determine whether an individual will respond similarly. For severe anxiety as a primary condition, the current evidence is limited.


Evidence for Use in Managing Acute Insomnia

The research base concerning Danazol and acute insomnia is mainly composed of documentation from adverse event listings and descriptive case reports. Studies exploring short-term symptom changes were not designed to evaluate Danazol as a primary sleep aid.

Studies were applied in contexts involving fluctuating or unstable symptoms. These studies monitored for outcomes related to systemic or functional imbalance, typically occurring in populations being treated for hormone-related issues. The evidence reflects these varying symptom burdens.

Findings describe patterns observed in the studies where insomnia or sleep disturbances were recorded by patients or clinicians. Studies monitored for outcomes related to systemic or functional imbalance, but they do not typically use objective measures like standardized sleep quality scales or polysomnography. This data helps contextualize how patients reported their experience during treatment for other conditions, but certainty remains low regarding research exploring a direct therapeutic role for acute insomnia.

Key Studies & References MedlinePlus: Danazol Drug Information - General purpose and hormonal effect

Frequently Asked Questions (FAQ)

Common questions about Elle (FAQ)


Q: What should I generally expect during the first few days of taking Elle?

Official documentation lists common changes that may be experienced when starting this medication, including acne, hot flashes, weight gain, nervousness, and emotional changes. These effects are often related to the drug's activity as a synthetic steroid. Individual experiences with the medication can vary.


Q: If a dose of Elle is missed, what is the general guidance provided in official materials?

Official guidance suggests that if a dose is remembered soon after the scheduled time, it may be taken. If it is close to the time for the next scheduled dose, the advice is generally to skip the missed one. It is advised not to take two doses at once, as this is against general regulatory advice.


Q: Is Elle considered a controlled substance by regulatory bodies?

According to official US regulatory sources, the active ingredient in Elle, Danazol, is not classified as a controlled substance. This indicates that it is not categorized under the schedules that govern drugs with a high potential for abuse or dependence.


Q: Is it common to feel tired or fatigued while taking Elle?

Unusual tiredness, weakness, or fatigue is listed among the less frequently reported side effects in regulatory-based summaries. While common effects include nervousness, generalized fatigue is reported less often.


Q: Is hair loss or thinning associated with the use of Elle?

Hair loss, including a pattern resembling male baldness, is listed in regulatory summaries as one of the potential androgenic effects of the medication.


Q: Is it considered normal to have mild nausea when first starting Elle?

Mild nausea and vomiting are listed as common gastrointestinal side effects, occurring in 1% to 10% of patients in clinical settings. This side effect has been reported in clinical settings.


Q: Is it safe to take Elle with vitamins or common dietary supplements?

Official patient safety sections strongly recommend informing your healthcare provider about all concomitant products you use. This includes any vitamins, dietary supplements, and over-the-counter drugs. Sharing this information helps the healthcare provider check for potential interactions.


Q: What are the described signs and symptoms of a severe allergic reaction to Elle?

Symptoms of a severe allergic reaction, as described in regulatory-based materials, typically include skin rash, itching, hives, or swelling. Severe reactions can include swelling of the face, lips, tongue, or throat, and difficulty breathing.


Q: Can Elle be used safely by older adults (seniors)?

While the FDA label includes a section on Geriatric Use, it often notes that clinical studies did not enroll a large number of subjects aged 65 and over. Due to the potential for impaired kidney, liver, or heart function in seniors, treatment in this population is generally approached with caution.


Q: Is Elle safe to use while breastfeeding according to official safety classifications?

According to official safety classifications, Elle is contraindicated (must not be used) while breastfeeding. This restriction is due to the drug's classification and the potential for effects on the infant.


Q: Are there any reports of long-term health effects of Elle after treatment has ended?

Regulatory documentation notes that some effects may be irreversible even after the medicine is stopped. Specifically, persistent voice changes, such as hoarseness or deepening of the voice, have been noted in regulatory reports as irreversible after the medication is discontinued.


Q: Can Elle potentially make other existing conditions, like high blood pressure, worse?

Official guidance advises caution for patients with heart conditions or high blood pressure, as the medication has been associated with fluid retention (edema). This association is why caution is recommended for these pre-existing conditions.


Q: Does Elle have any known effect on fertility in men or women?

Studies and official information indicate that Elle can affect the reproductive system. In women, the drug works by suppressing the ovarian cycle, and it may lead to prolonged amenorrhea after the therapy has concluded. In men, the drug's effects have been associated with changes such as sperm abnormalities and testicular changes.


Q: What is the general success rate of Elle as reported in clinical trial data?

Clinical trial summaries for its approved uses, such as endometriosis, have documented high rates of symptomatic relief and objective improvement in some controlled research studies. These findings are based on controlled research.


Q: Can Elle potentially affect my sleep patterns or cause insomnia?

Sleep disorders, including insomnia, are listed in regulatory-based adverse reaction tables, typically under the category of Psychiatric side effects. Sleep disorders have been reported by individuals using the medication.


Q: Why do official documents warn against the abrupt discontinuation of Elle?

The official protocol advises gradual dose reduction, especially for long-term use. This approach is generally advised to ensure the continuation of protective effects and manage underlying conditions. For this reason, stopping the medication abruptly is generally advised against.

How should Elle be stored and disposed of?

How to Store and Dispose of Elle (Danazol)

The storage and disposal of Elle (Danazol capsules) must adhere strictly to official regulatory guidelines to maintain product quality and ensure safety.


Official Storage Requirements

Temperature and Environment: Store the medication at room temperature, specifically not exceeding 30 C. The capsules must be protected from light, moisture, and excessive heat. Official instructions direct keeping the medicine from freezing.

Container and Security: The product must be stored in a tightly closed, light-resistant container.

Child Safety: Due to potential harm, the medication must be stored locked up and kept out of the sight and reach of children.


Official Disposal Instructions

Pharmaceutical Waste: Do not keep outdated or unused medicine. Disposal must be performed in accordance with local/regional/national regulations for pharmaceutical waste. Due to the drug's classification, it is often required that disposal avoids standard household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elle found in:

A-Z Index: